Hepatitis B Virus Seroprevalence in Ayacucho, Peru: A Comprehensive Review Across the Pre-Vaccination and Post-Vaccination Periods.

IF 5.2 3区 医学 Q1 IMMUNOLOGY
Vaccines Pub Date : 2025-08-28 DOI:10.3390/vaccines13090916
Homero Ango-Aguilar, Jimmy Ango-Bedriñana, Obert Marín-Sánchez, Ruy D Chacón
{"title":"Hepatitis B Virus Seroprevalence in Ayacucho, Peru: A Comprehensive Review Across the Pre-Vaccination and Post-Vaccination Periods.","authors":"Homero Ango-Aguilar, Jimmy Ango-Bedriñana, Obert Marín-Sánchez, Ruy D Chacón","doi":"10.3390/vaccines13090916","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatitis B virus (HBV) infection remains a global public health concern, with perinatal transmission as the primary route in endemic populations. Ayacucho is a priority region due to its high incidence (second nationally between 2019 and 2024) and the significant decline in vaccination coverage (~15%). This study aims to synthesize existing epidemiological evidence on HBV seroprevalence in Ayacucho, Peru, emphasizing temporal changes observed before and after the implementation of vaccination programs to inform control strategies. This review was conducted, integrating data from diverse population groups, including children, pregnant women, blood donors, high-risk individuals (military personnel, female sex workers, prisoners), and household contacts, to identify transmission patterns and evaluate the impact of immunization efforts. Historically, Ayacucho was hyperendemic, with an HBsAg prevalence of 20% in Huanta (1985-1986) and a high mortality from liver diseases. The introduction of a vaccination in the 1990s led to a drastic reduction in infection rates among children, from 24.4-30.4% (1994) to 2.3-5.1% (1997), and improved overall Expanded Program on Immunization (EPI) coverage. However, recent data (2000-2024) reveal a concerning increase in HBV cases since 2012, with peaks in 2016 and 2023, correlating with a decline in vaccination rates post-2021. HBV prevalence remains elevated among high-risk populations-including military personnel, female sex workers, and prisoners-as well as among blood donors (HBsAg: 3.73-5.0%; anti-HBc: 21-33%). In addition, significant knowledge gaps and low adherence to EPI strategies were observed. Despite initial vaccination success, Ayacucho faces a resurgence of HBV infection, exacerbated by declining vaccine coverage and vulnerabilities in high-risk populations. Reinforcing immunization programs and screening strategies is urgent to control and eventually eliminate HBV cases in the region.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 9","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474373/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines13090916","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatitis B virus (HBV) infection remains a global public health concern, with perinatal transmission as the primary route in endemic populations. Ayacucho is a priority region due to its high incidence (second nationally between 2019 and 2024) and the significant decline in vaccination coverage (~15%). This study aims to synthesize existing epidemiological evidence on HBV seroprevalence in Ayacucho, Peru, emphasizing temporal changes observed before and after the implementation of vaccination programs to inform control strategies. This review was conducted, integrating data from diverse population groups, including children, pregnant women, blood donors, high-risk individuals (military personnel, female sex workers, prisoners), and household contacts, to identify transmission patterns and evaluate the impact of immunization efforts. Historically, Ayacucho was hyperendemic, with an HBsAg prevalence of 20% in Huanta (1985-1986) and a high mortality from liver diseases. The introduction of a vaccination in the 1990s led to a drastic reduction in infection rates among children, from 24.4-30.4% (1994) to 2.3-5.1% (1997), and improved overall Expanded Program on Immunization (EPI) coverage. However, recent data (2000-2024) reveal a concerning increase in HBV cases since 2012, with peaks in 2016 and 2023, correlating with a decline in vaccination rates post-2021. HBV prevalence remains elevated among high-risk populations-including military personnel, female sex workers, and prisoners-as well as among blood donors (HBsAg: 3.73-5.0%; anti-HBc: 21-33%). In addition, significant knowledge gaps and low adherence to EPI strategies were observed. Despite initial vaccination success, Ayacucho faces a resurgence of HBV infection, exacerbated by declining vaccine coverage and vulnerabilities in high-risk populations. Reinforcing immunization programs and screening strategies is urgent to control and eventually eliminate HBV cases in the region.

在阿亚库乔,秘鲁乙型肝炎病毒血清阳性率:在疫苗接种前和疫苗接种后时期的全面审查。
乙型肝炎病毒(HBV)感染仍然是一个全球公共卫生问题,在流行人群中,围产期传播是主要途径。阿亚库乔是一个重点地区,因为其发病率高(2019年至2024年期间在全国排名第二),疫苗接种覆盖率大幅下降(约15%)。本研究旨在综合现有的秘鲁阿亚库乔地区HBV血清阳性率的流行病学证据,强调在实施疫苗接种计划前后观察到的时间变化,为控制策略提供信息。本次审查整合了来自不同人群的数据,包括儿童、孕妇、献血者、高危人群(军事人员、女性性工作者、囚犯)和家庭接触者,以确定传播模式并评估免疫接种工作的影响。从历史上看,阿亚库乔是高地方性的,环塔的HBsAg患病率为20%(1985-1986),肝脏疾病死亡率高。20世纪90年代开始接种疫苗,导致儿童感染率大幅下降,从24.4-30.4%(1994年)降至2.3-5.1%(1997年),并提高了扩大免疫规划(EPI)的总体覆盖率。然而,最近的数据(2000-2024年)显示,自2012年以来HBV病例出现了令人担忧的增长,2016年和2023年达到高峰,这与2021年后疫苗接种率下降有关。高危人群(包括军事人员、女性性工作者和囚犯)以及献血者(HBsAg: 3.73-5.0%;抗hbc: 21-33%)中HBV的患病率仍然升高。此外,观察到显著的知识差距和对EPI策略的低依从性。尽管疫苗接种取得了初步成功,但阿亚库乔面临着HBV感染的死灰复燃,而疫苗覆盖率的下降和高危人群的脆弱性加剧了这种情况。加强免疫规划和筛查战略是控制并最终消除该地区乙型肝炎病例的迫切需要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vaccines
Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍: Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信